Protein kinases are critical regulators of cellular signaling, but precise modulation of their activity remains challenging due to their high structural conservation. Here, we present de novo designed genetically encoded miniproteins capable of activating or inhibiting focal adhesion kinase (FAK) by directly targeting the kinase domain itself. Among 96 binders designed to stabilize distinct conformational states of FAK, 33 modulated kinase activity. Biochemical characterization of the four most potent modulators revealed that two designs inhibit FAK with low-nanomolar IC50 values while the remaining two potentiated FAK activity by more than two-fold. When expressed in cells, the modulators preserved the same inhibitory and activating effects observed in vitro, establishing that designed conformational binders can directly tune FAK signaling in living cells. Taking advantage of the high similarity between kinases, we redesigned the FAK inhibitors to inhibit Src kinase. Our approach establishes a versatile platform for selective and genetically encoded kinase control as a way to rewire cell signaling and as a starting point for the discovery of novel modulatory sites of kinases.
Together, these examples define an expanding pharmacological vocabulary for kinase drug discovery: one that asks not only whether a molecule inhibits its target kinase, but how ligand binding rewires protein stability, interactions, localisation, and function.
J. Diepeveen, Z. Kozicka· Chimia (Basel)· 0 citations
The structural and medicinal chemistry principles underlying (i) allosteric inhibition and (ii) proximity-induced degradation are summarized, with an emphasis on design logic, structure-activity relationships, and key liabilities in the beyond rule of five space.
Mei Zhou, Linshan Li, Xiao-Juan Tang et al.· Future Medicinal Chemistry· 0 citations
Members of the DYRK kinase family have been implicated in the regulation of key metabolic processes. In particular, DYRK1B plays a central role in hepatic lipid metabolism and fatty liver disease. Notably, these functions depend not only on the enzyme’s catalytic activity but also on scaffolding properties. Consequentl...
Miriam S. Ems, Mattias F. Lindberg, Till Adhikary et al.· ACS Pharmacology & Translati...· 0 citations
It is proposed that the order of kinases in cascades is dictated by their conformational character, a mechanism amplified in cascade-enriched biomolecular condensates—establishing design principles for pathway-selective, cascade-directed therapeutics.
R. Nussinov, Clil Regev, H. Jang· RSC Chemical Biology· 0 citations
Developing selective covalent-allosteric Akt inhibitors targeting Akt2 and Akt3 while sparing Akt1 is reported, which establishes a framework for the development of isoform-selective therapeutics and highlights the potential for unraveling isoform-specific functions in signaling pathways relevant to cancer biology.
G. D'Angelo, Kosmas Alexandros Pervanidis, Ioannis Athanasiadis et al.· Angewandte Chemie· 1 citation
It is shown that inhibitor size and flexibility affect binding mechanisms and have implications on kinetics, distinct from previous computational studies.
A. Shinobu, Suyong Re, Hiraku Oshima et al.· Journal of Physical Chemistr...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.